<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112915</url>
  </required_header>
  <id_info>
    <org_study_id>02</org_study_id>
    <nct_id>NCT03112915</nct_id>
  </id_info>
  <brief_title>Comparison of the Quadratus Lumborum Block With the Transversus Abdominis Plan Block</brief_title>
  <official_title>Comparison of Quadratus Lumborum Block and Transversus Abdominis Plane Block for Postoperative Pain Control After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kecioren Education and Training Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kecioren Education and Training Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators aimed to compare the Quadratus Lumborum Block and the
      Transversus Abdominis Plan Block for postoperative pain control after laparoscopic
      cholecystectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After ethical committee approval, informed written consent will be obtained from all
      patients.

      A Sample size of 60 patients (30 per group) was calculated based on 15% reduction in morphine
      consumption with 0.05% significance and a power of 0.8.

      Consenting patients scheduled to have elective laparoscopic cholecystectomy under general
      anesthesia will be randomized to receive bilateral QLB or TAP before the surgery. The dose of
      local anesthetic in both groups will be 20 ml 0.25% Bupivacaine. Allocation to either group
      will be done using permuted block randomization method.

      Patients will be taken to the block room 1 hour before surgery. ECG, NIBP and SpO2 monitor
      will be done. The IV access route will be provided. The patient will be given 0.03 mg / kg IV
      midazolam for routine premedication. Block will be applied by a blind anesthetist to the
      other data of the study. Under ultrasound guidance a 22 Gauge Sonoplex needle will be used
      for both techniques. The calculated dose of local anesthetic will be injected bilaterally
      with intermittent aspiration. The spread of injectate will be seed on ultrasound.

      The procedure time for both blocks will be recorded and 30 minutes after the procedure is
      completed, and the patient will be taken to the operation room. General anesthesia will be
      applied to the patient in the operation procedure in the standard procedure. Intraoperative
      heart rate and / or mean arterial pressure is increased to 20% of the basal value and 0.5 mcg
      / kg IV fentanyl will be added. 30 minutes before the end of operation, 1 mg IV paracetamol
      and NSAID (dexketoprofen) 50 mg IV will be administered to the patient before extubation. The
      patient will be infected with IV PCA in the morphine. PC 1 mg IV bolus dose will be adjusted
      to 10 minutes of locked-out period. In the postoperative period, 4 * 1 gr / 24 h IV
      paracetamol will be given to each patient.

      All patients will be assessed postoperatively by a blinded investigator: in the
      post-anesthesia care unit and at 0, 2, 4, 6, 12 and 24 h postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">September 12, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind randomized controlled trail</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind randomized controlled trail</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total cumulative morphine consumption</measure>
    <time_frame>24 hour</time_frame>
    <description>Total cumulative morphine dose in mg used in the first 24 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of postoperative pain via visual analogue pain scale (VAS)</measure>
    <time_frame>24 hour</time_frame>
    <description>VAS range from 0 for no pain to 10 for worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea or vomiting</measure>
    <time_frame>24 hour</time_frame>
    <description>0 = No Nausea
= Mild Nausea.
= Moderate 3 = Severe Nausea or Vomiting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>QLB: Quadratus lumborum block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)
patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP: transversus abdominis plan block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAP: Transversus abdominis plane block (TAP)
patients will receive a bilateral TAP block using Bupivicaine 0.25%</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quadratus lumborum block</intervention_name>
    <description>QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position</description>
    <arm_group_label>QLB: Quadratus lumborum block</arm_group_label>
    <other_name>QLB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transversus abdominis plan block</intervention_name>
    <description>TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position</description>
    <arm_group_label>TAP: transversus abdominis plan block</arm_group_label>
    <other_name>TAP block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA 1-2-3

          -  elective Laparoscopic cholecystectomy

          -  19-65 years

          -  Written informed consent

        Exclusion Criteria:

          -  Patient refusal Local infection at the site of injection

          -  Allergy to study medications Sepsis Anatomic abnormalities Systemic anticoagulation or
             coagulopathy - Inability to comprehend or participate in pain scoring system

          -  Inability to use intravenous patient controlled analgesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>merve kacan</last_name>
    <phone>+90 05532529902</phone>
    <email>drmervekacan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kecioren ETH</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>merve kacan</last_name>
      <phone>+9005532529902</phone>
      <email>drmervekacan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>handan gulec</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>berrin kosar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>eyup horasanli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>merve kacan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28154824</url>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27755488</url>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>September 24, 2017</last_update_submitted>
  <last_update_submitted_qc>September 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kecioren Education and Training Hospital</investigator_affiliation>
    <investigator_full_name>Merve Kacan</investigator_full_name>
    <investigator_title>Assistant doctor</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>Laparoscopic cholecystectomy</keyword>
  <keyword>Quadratus lumborum block</keyword>
  <keyword>transversus abdominis plan block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

